Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas.

Affiliation auteurs!!!! Error affiliation !!!!
TitreUnicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas.
Type de publicationJournal Article
Year of Publication2018
AuteursConroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AChia-chi, Raoul J-L, Chone L, Francois E, Artru P, Biagi JJoseph, Lecomte T, Assenat E, Faroux R, Ychou M, Volet J, Sauvanet A, Jouffroy-Zeller C, Rat P, Castan F, Bachet J-B
JournalJOURNAL OF CLINICAL ONCOLOGY
Volume36
Date PublishedJUN 20
Type of ArticleMeeting Abstract
ISSN0732-183X
DOI10.1200/JCO.2018.36.18_suppl.LBA4001